( re from 800 to 1000 GPCRs on the human...)Biotech executive books a career flight that's closer to home

re from 800 to 1,000 GPCRs on the human genome. Of those, roughly 400 are thought to be pharmaceutically relevant, but only 40 have been successfully targeted by commercial drugs - representing $50 billion in annual sales - and many of those drugs have side effects.

Caden Biosciences might be able to partner with a big pharma company to pinpoint the remaining intractable targets, and addr......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 02/19/07


Page: 1 2 3
Related biology technology :

1. Biotech officials praise focus of new venture fund
2. Gala Biotech among companies sold for $3.3 billion
3. Biotech with Madison ties raises $21M in capital
4. Biotech firm uses live heart tissue in drug screens
5. Biotech talent drew venture-funded firm to Madison
6. Biotech firm has strokes, Alzheimers in its sights
7. 42 days until the 2006 Olympics of Biotechnology in Chicago
8. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
9. Biotech leads list of top U.S. companies to work for
10. Biotech flourishes in 2005 while Big Pharma is on the decline
11. Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says